Nautilus Biotechnology, Inc. (NASDAQ: NAUT) reported Q4 EPS of ($0.14), $0.02 better than the analyst estimate of ($0.16).

2024 Outlook:
The company expects full year operating expense to grow by approximately 25% relative to 2023
The company expects that cash and cash equivalents and investments of $264.1 million as of December 31, 2023 to provide a runway into the second half of 2026.
The company expects expect to launch our platform, instruments, consumables, and software in 2025.

For earnings history and earnings-related data on Nautilus Biotechnology, Inc. (NAUT) click here.